STERiJECT™ Ophthalmic
Low Dead Space.
FDA 510(k) issued for ophthalmic injections.
✔︎ FDA 510(k) cleared for ophthalmic use
✔︎ Optimal flow rate: Large innerdiameter
✔︎ Accurate dose injection: near zero dead space (BMJ, 2021)
✔︎ Optimal patient comfort: available in 30G-34G bevel
FDA cleared for ophthalmic use.
Eye clinics still use non-ophthalmic needles.
The sharp increase in retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy, and retinal vein occlusion has led to a surge in intravitreal injection procedures. Despite this, many practices still rely on hypodermic needles not originally intended for use in the eye. STERiJECT™ was created to meet this unmet clinical need—offering a dedicated device for ophthalmologists and retina specialists that prioritizes dose control, patient comfort, and sterility.
Regular Hypodermic Needle
Non compliant
Not tested
Endotoxin limit 20.0 EU/device
~ 0.04 ml
STERiJECT Ophthalmic Needle
FDA 510(k) issued
USP 789 compliant
Endotoxin limit 0.2 EU/device
~ 0.0 ml
Optimal flow rate.
TSKiD large needle inner diameters deliver ideal product flow for controlled injections.
TSKiD™ Technology sets a new standard in needle performance by incorporating enlarged inner diameters, enabling smoother, more controlled injections. In ophthalmic procedures, maintaining an optimal flow rate is essential—neither too low nor excessively high.
When the flow rate falls below 5N, insufficient tactile feedback may hinder precise drug delivery. Conversely, flow rates exceeding 15N can lead to patient discomfort and require greater injection force, potentially causing hand and finger fatigue for clinicians performing multiple injections throughout the day.
Accurate dose injection.
STERiJECT Low Dead Space needles ensure close to zero product loss and accurate dose delivery.
LDS (Low Dead Space) needles are designed to support precise and consistent dosing—an essential feature when delivering very small volumes of medication. In ophthalmic treatments, where doses as small as 0.05 mL are common, even slight variances in delivery can impact therapeutic outcomes.
By minimizing residual volume left in the syringe, LDS needles help ensure that the intended dose is fully administered to the patient. This level of accuracy is especially critical in clinical applications where consistency, safety, and treatment efficacy depend on exact dosing every time.
Order STERiJECT Ophthalmic LDS Needles
Buy nowProduct loss ~0.0 ml.
Eliminating dead space in the needle hub can save up to 0.042 ml per needle.
Each LDS (Low Dead Space) needle can save up to 0.042 mL of medication per syringe—an amount that may seem minor individually but becomes highly significant when scaled across high-volume production. For large clinics and compounding pharmacies preparing hundreds or thousands of syringes with ophthalmic drugs, this reduction in residual waste can translate to a considerable increase in usable doses from each vial.
Given the high cost of many ophthalmic medications, minimizing drug loss at the needle level can result in substantial financial savings over time. This efficiency not only reduces costs but also helps maximize inventory, making LDS needles a valuable tool for improving operational margins in high-throughput environments.
Optimal patient comfort.
Available in sizes from 30G up to 34G, reducing risk of vitreous flux and hemorrhaging.
STERiJECT™ ophthalmic needles are available in sizes ranging from 30G to 34G, offering a balance between precision and patient comfort. These fine-gauge options are designed specifically for intravitreal injections, where minimizing tissue disruption is essential.
The needle design helps reduce the risk of vitreous reflux and subconjunctival hemorrhage, while maintaining an optimal flow rate and injection force. This ensures consistent drug delivery with minimal discomfort, even during high-volume clinical use.
Developed in collaboration with ophthalmic specialists.
STERiJECT is trusted by retina specialists and ophthalmic pharma companies across the globe.
